Work

Beyond IL-1β: A Hypothesis Linking Interictal S100A12, IL-18 and Serum Amyloid A to Mast Cell and Basophil Activation as a Possible Mechanism for Interictal Symptoms in Familial Mediterranean Fever

Year: 2026
Type: preprint
Abstract: Familial Mediterranean Fever (FMF) is a monogenic autoinflammatory disorder classically attributed to MEFV mutations, pyrin inflammasome activation, and episodic interleukin-1β (IL-1β) release. Although daily colchicine and targeted IL-1 inhibitors effectively prevent acute serositis flares in most patients, a substantial subset experiences persistent, debilitating interictal symptoms—including chronic fatigue, myalgia, arthralgia, and hypersensitivity-like manifestations—during clinically attack-free periods. Because IL-1β secretion is pulsatile, the classic paradigm may not fully explain this smoldering interictal morbidity. A recent cohort study also reported mast cell activation symptoms and elevated histamine in FMF without identifying the responsible mediators. Here, we propose a partly IL-1–independent innate effector axis linking subclinical neutrophil and hepatic activation to chronic mast cell and basophil activation. Its best-supported component is residual neutrophil-derived S100A12, which remains elevated in some colchicine-treated patients with persistent symptoms and can activate mast cells in vitro. Integrating FMF pathophysiology with mast cell biology, we hypothesize that: (1) spontaneous, Gasdermin D- and reactive oxygen species-dependent neutrophil cell death observed ex vivo in patients in clinical remission may release increased amounts of S100A12, which can activate tissue mast cells through a receptor that remains to be identified; (2) interictally elevated IL-18 (so far reported in small studies with limited genotype data) may activate circulating basophils (in the presence of IL-3) to sustain systemic histamine and Th2 cytokine release; and (3) as a more speculative amplifier that depends largely on IL-1 and IL-6, persistently elevated interictal Serum Amyloid A (SAA) may recruit mast cells through a pathway consistent with Formyl Peptide Receptor 2 (FPR2) and, more speculatively, prime them via epithelial IL-33 secretion. This tripartite mechanism could help explain part of the interictal symptom burden, particularly in patients with incomplete biochemical remission, and generates testable biomarker predictions. Mast cell–directed approaches, such as mast cell stabilizers and mediator blockers, would merit controlled evaluation only after those predictions have been tested.
Language: English
Open Access status: green
OpenAlex ID: W7233782380
Cites:
Cited by:
Related to: 10